1. Volume 149, Issue 2, Pages 350-355.e2 (August 2015)
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis 
Johannan F. Brandse, Gijs R. van den Brink, Manon E. Wildenberg, Desiree van der Kleij, Theo Rispens, Jeroen M. Jansen, Ron A. Mathôt, Cyriel Y. Ponsioen, Mark Löwenberg, Geert R.A.M. D’Haens 
Gastroenterology 
Volume 149, Issue 2, Pages e2 (August 2015)
DOI: /j.gastro
Copyright © 2015 AGA Institute Terms and Conditions

2. Figure 1
Infliximab concentrations in fecal supernatant 14 days after the first infliximab infusion.
Gastroenterology  , e2DOI: ( /j.gastro )
Copyright © 2015 AGA Institute Terms and Conditions

3. Figure 2
Fecal infliximab concentrations up to 14 days after IFX therapy for clinical response at week 2, endoscopic response at week 8 and clinical response at 3 months. IFX: infliximab, CR: clinical response, NR: non-response, ER: endoscopic response, w2: week 2, w8: week 8, 3m: 3 months.
Gastroenterology  , e2DOI: ( /j.gastro )
Copyright © 2015 AGA Institute Terms and Conditions

4. Supplementary Figure 1
Correlation of fecal IFX concentration at day 1 and serum infliximab concentration at week 2 (before second infusion).
Gastroenterology  , e2DOI: ( /j.gastro )
Copyright © 2015 AGA Institute Terms and Conditions